Witiak D T, Lee H J, Goldman H D, Zwilling B S
J Med Chem. 1978 Dec;21(12):1194-7. doi: 10.1021/jm00210a004.
The synthesis for cis-4,4' (1,2-cyclopropanediyl)bis(2,6-piperazinedione) (cis-3) is discussed. Stereoselective effects on metastases of cis-3 and the previously reported trans-2 isomer were compared to conformationally mobile ICRF-159 using a Syrian hamster lung adenocarcinoma (LG1002). Whereas ICRF-159 and cis-3 significantly inhibited lung metastases the trans-2 isomer significantly increased the number of metastatic nodules in the lung. Thus, these studies have revealed that, at least in one tumor model, antimetastatic activity can be separated from metastatic potentiating activity by controlling drug geometry.
讨论了顺式-4,4'-(1,2-环丙烷二基)双(2,6-哌嗪二酮)(顺式-3)的合成。使用叙利亚仓鼠肺腺癌(LG1002),将顺式-3和先前报道的反式-2异构体对转移的立体选择性作用与构象可变的ICRF-159进行了比较。虽然ICRF-159和顺式-3显著抑制肺转移,但反式-2异构体显著增加了肺中转移结节的数量。因此,这些研究表明,至少在一种肿瘤模型中,通过控制药物几何结构,可以将抗转移活性与转移增强活性分开。